Clinical trials: Cognitive Manifestations
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Infertility, Miscarriage
Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy
This study evaluates the effect of single embryo transfer (SET) with and without array CGH for the evaluation of the complete chromosome complement of the blastocyst. Patients will be allocated at random into two groups.
- Trial name
- NCT01332643
- Testing
- Preimplantation Genetic Diagnosis
- Where
- Peru
- Volunteers
- 120 people
- Sponsor
- Reprogenetics
Hallux Valgus, Bunionectomy
Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy
This is a Phase 2, randomized, double-blind, active-controlled, dose-escalation study evaluating the safety, pharmacokinetics, efficacy, and pharmacodynamics of ALX006, an extended-release bupivacaine formulation, administered as…
- Trial name
- NCT07574385
- Testing
- ALX006 (bupivacaine extended-release injection), Bupivacaine Hcl 0.25% Inj, Sciatic Nerve Block
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Rebel Medicine Inc
Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients
First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic
According to the local guidelines (Recommendation for General Practitioners), the first choice Anti-Depressant (AD) in Major Depressive Disorder (MDD) in primary care should be selective serotonin reuptake inhibitors (SSRI), e.g.
- Conditions
- Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients, Newly Diagnosed Depression
- Trial name
- FIAT (NCT05291897)
- Where
- 6 sites in Czechia
- Volunteers
- 28 people
- Sponsor
- Angelini Pharma Česká republika s.r.o.
Bipolar Disorder
Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents
A clinical study to determine the safety and effectiveness of risperidone compared with placebo in the treatment of bipolar disorder (manic or mixed type) in children and adolescents aged 10 to 17 years.
- Trial name
- NCT00076115
- Testing
- Risperidone
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- DAYBREAK-ALZ (NCT02783573)
- Testing
- Lanabecestat
- Where
- 262 sites in United States, Canada and 16 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca
Dyslexia, Reading Disability
Brain Stimulation Paired With Structured Reading Instruction in Children With Dyslexia
This study investigates whether transcranial electrical stimulation (tES) delivered during structured reading instruction affects reading proficiency in children with developmental dyslexia and related reading disabilities.
- Trial name
- NCT07762365
- Testing
- Active transcranial electrical stimulation (tES)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- General Neuro Inc.
Aphasia, Global, Stroke
tDCS and Speech Therapy to Improve Aphasia
To study the effect of combined tDCS plus speech therapy compared to sham-tDCS plus speech therapy in subacute stroke patients suffering from moderate or severe aphasia.
- Conditions
- Aphasia, Global, Stroke, Transcranial Direct Current Stimulation, Speech Therapy
- Trial name
- MP-LOGA (NCT02395874)
- Testing
- tDCS + speech therapy
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Medical Park AG
Painful Diabetic Neuropathy
A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
This trial is assessing the analgesic efficacy and safety of a new central analgesic in subjects with pain due to diabetic peripheral neuropathy (DPN).
- Trial name
- NCT01056315
- Testing
- GRT3938Y
- Where
- 61 sites in United States
- Volunteers
- 553 people
- Sponsor
- Grünenthal GmbH
Postoperative Pain
Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty
The primary objective of this study was to demonstrate the superiority of SKY0402 over conventional, commercially-available bupivacaine HCl with respect to the duration of the analgesic effect achieved by a single local…
- Trial name
- NCT01206608
- Testing
- SKY0402 + bupivacaine HCl, Mid-dose SKY0402 + bupivacaine HCl
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Syncope, Cryptogenic Stroke
BIO|STREAM.ICM France
The main objective of the BIO│STREAM.ICM France submodule is to provide clinical evidence from patients in France on safety and efficacy of the BIOMONITOR system
- Trial name
- NCT04206774
- Where
- 3 sites in France
- Volunteers
- 92 people
- Sponsor
- Biotronik SE & Co. KG
Neuralgia
P4 (Pregabalin for Peripheral Posttraumatic Pain)
To evaluate the efficacy of pregabalin compared to placebo in the treatment of posttraumatic peripheral neuropathic pain
- Trial name
- P4 (NCT00292188)
- Testing
- pregabalin
- Where
- 44 sites in Belgium, Canada and 9 more
- Volunteers
- 255 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Mucopolysaccharidosis II
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
AGT-182 is a fusion protein containing idursulfase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously.
- Trial name
- NCT02262338
- Testing
- AGT-182
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- ArmaGen, Inc
Pain, Chronic
Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
The purpose of this study is to evaluate the efficacy and safety of Canadá association in the treatment of chronic pain
- Trial name
- CANADÁ (NCT05125978)
- Testing
- Canadá, Dipyrone, Tramadol hydrochloride
- Sponsor
- EMS
Bipolar Disorders, Manic Disorder
A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder
The purpose of the study is to evaluate the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo as add-on therapy to mood stabilizers in the treatment of manic episodes associated with bipolar…
- Trial name
- NCT00253149
- Testing
- risperidone
- Volunteers
- 158 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
AMN, AMN Gene Mutation
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
The course of AMN-related disabilities over time is poorly or incompletely understood due to a limited number of patients and lack of treatments.
- Conditions
- AMN, AMN Gene Mutation, X-ALD
- Trial name
- CYGNET (NCT05008874)
- Testing
- Natural History Observation
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- SwanBio Therapeutics, Inc.
Pain Management, Osteoarthritis
Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.
The goal of this clinical trial is to learn if fixed-dose combination etoricoxib 90 mg + diacerein 50 mg capsule works to treat knee/hip osteoarthritis-associated pain in adults. It will also learn about the safety of the drug.
- Trial name
- NCT07549386
- Testing
- Etoricoxib 90 mg + diacerein 50 mg, Meloxicam 15 mg + diacerein 50 mg
- Where
- 4 sites in Mexico
- Volunteers
- 123 people
- Sponsor
- Laboratorios Liomont
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Cognitive Symptoms
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).
- Trial name
- NCT00134953
- Testing
- Rivastigmine
- Volunteers
- 24 people
- Sponsor
- Novartis